NASDAQ:NK Nantkwest Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nantkwest Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.49 +0.16 (+1.92 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$8.13Now: $8.49▼$8.7150-Day Range$6.37MA: $8.51▼$13.4352-Week Range$1.04Now: $8.49▼$15.70Volume1.63 million shsAverage Volume1.94 million shsMarket Capitalization$916.67 millionP/E RatioN/ADividend YieldN/ABeta2.54 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingNantkwest has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Nantkwest has a forecasted upside of 112.0% from its current price of $8.49.Amount of Analyst CoverageNantkwest has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesNantkwest has received 271 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNantkwest has received 259 “underperform” votes. (Add your “underperform” vote.)Community SentimentNantkwest has received 51.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote “Outperform” if you believe NK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNantkwest does not currently pay a dividend.Dividend GrowthNantkwest does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nantkwest insiders have bought 981.47% more of their company's stock than they have sold. Specifically, they have bought $44,965,200.00 in company stock and sold $4,157,792.00 in company stock.Percentage Held by Insiders72.08% of the stock of Nantkwest is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.72% of the stock of Nantkwest is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nantkwest are expected to decrease in the coming year, from ($0.75) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nantkwest is -11.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nantkwest is -11.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNantkwest has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.02 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NK Previous Symbol CUSIPN/A CIK1326110 Webwww.nantkwest.com Phone858-633-0300Debt Debt-to-Equity Ratio0.06 Current Ratio6.76 Quick Ratio6.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales22,916.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book6.90Profitability EPS (Most Recent Fiscal Year)($0.70) Net Income$-65,790,000.00 Net Margins-162,086.03% Return on Equity-52.71% Return on Assets-44.50%Miscellaneous Employees161 Outstanding Shares107,970,000Market Cap$916.67 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $8.49 +0.16 (+1.92 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NK News and Ratings via Email Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Nantkwest (NASDAQ:NK) Frequently Asked Questions How has Nantkwest's stock price been impacted by Coronavirus (COVID-19)? Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NK stock has increased by 141.2% and is now trading at $8.49. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Nantkwest? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nantkwest. When is Nantkwest's next earnings date? Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Nantkwest. How were Nantkwest's earnings last quarter? Nantkwest Inc (NASDAQ:NK) posted its quarterly earnings results on Friday, August, 7th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. Nantkwest had a negative net margin of 162,086.03% and a negative return on equity of 52.71%. View Nantkwest's earnings history. What price target have analysts set for NK? 1 brokers have issued 1 year price objectives for Nantkwest's shares. Their forecasts range from $18.00 to $18.00. On average, they expect Nantkwest's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price. View analysts' price targets for Nantkwest. Who are some of Nantkwest's key competitors? Some companies that are related to Nantkwest include Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST), Legend Biotech (PCVX), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Revolution Medicines (RVMD), BAVARIAN NORDIC/S (BVNRY), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Sangamo Therapeutics (SGMO) and Beam Therapeutics (BEAM). View all competitors. What other stocks do shareholders of Nantkwest own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Opko Health (OPK), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX) and Inovio Pharmaceuticals (INO). Who are Nantkwest's key executives? Nantkwest's management team includes the following people: Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)Mr. Richard J. Tajak, Consultant (Age 66)Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62) When did Nantkwest IPO? (NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager. What is Nantkwest's stock symbol? Nantkwest trades on the NASDAQ under the ticker symbol "NK." Who are Nantkwest's major shareholders? Nantkwest's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.61%), Charles Schwab Investment Management Inc. (0.19%), Bank of New York Mellon Corp (0.18%), Nuveen Asset Management LLC (0.10%), Meridian Investment Counsel Inc. (0.10%) and California Public Employees Retirement System (0.06%). Company insiders that own Nantkwest stock include Barry J Simon, Frederick W Driscoll, John C Thomas, Patrick Soon-Shiong and Steve Gorlin. View institutional ownership trends for Nantkwest. Which major investors are selling Nantkwest stock? NK stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, and Bridgeway Capital Management Inc.. Company insiders that have sold Nantkwest company stock in the last year include Barry J Simon, Frederick W Driscoll, and John C Thomas. View insider buying and selling activity for Nantkwest. Which major investors are buying Nantkwest stock? NK stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Meridian Investment Counsel Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, Nantahala Capital Management LLC, Schonfeld Strategic Advisors LLC, and State of Wisconsin Investment Board. View insider buying and selling activity for Nantkwest. How do I buy shares of Nantkwest? Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nantkwest's stock price today? One share of NK stock can currently be purchased for approximately $8.49. How big of a company is Nantkwest? Nantkwest has a market capitalization of $916.67 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe. What is Nantkwest's official website? The official website for Nantkwest is www.nantkwest.com. How can I contact Nantkwest? Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
